Serum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection
To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked...
Saved in:
Published in | Frontiers in cellular and infection microbiology Vol. 10; p. 470 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
04.09.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection.
Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations.
Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485-1.000,
< 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16-96.85%) and 96.84% (95% confidence interval 95.17-97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL.
The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible. |
---|---|
AbstractList | To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection.
Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations.
Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485-1.000,
< 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16-96.85%) and 96.84% (95% confidence interval 95.17-97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL.
The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible. Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection.Methods: Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations.Results: Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485–1.000, p < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16–96.85%) and 96.84% (95% confidence interval 95.17–97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL.Conclusion: The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible. Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Methods: Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations. Results: Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485–1.000, p < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16–96.85%) and 96.84% (95% confidence interval 95.17–97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL. Conclusion: The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible. Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Methods: Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations. Results: Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485-1.000, p < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16-96.85%) and 96.84% (95% confidence interval 95.17-97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL. Conclusion: The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible.Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of SARS-COV-2 infection. Methods: Serum N protein level in SARS-COV-2 infected patients and non-SARS-COV-2 infected population was measured by enzyme-linked immunosorbent assay (ELISA) double antibody sandwich assay. Colloidal gold immunochromatography assay was used to detect serum N protein antibodies in the above populations. Results: Fifty cases of SARS-CoV-2 nucleic acid-positive and SARS-CoV-2 antibody-negative patients had a serum N protein positivity rate of 76%. Thirty-seven patients who were positive for serum SARS-CoV-2 antibody after infection had a serum SARS-CoV-2 N protein positivity rate of 2.7%. Serum N protein test results of 633 non-SARS-COV-2 infected patients, including pregnant women, patients with other respiratory infections, and individuals with increased rheumatoid factor were all negative, with serum N protein concentration <10.00 pg/mL at 100% specificity. Using SPSS 19.0 to calculate the receiver operating characteristic curve, the area under the curve was determined to be 0.9756 (95% confidence interval 0.9485-1.000, p < 0.0001), and sensitivity and specificity were 92% (95% confidence interval 81.16-96.85%) and 96.84% (95% confidence interval 95.17-97.15%), respectively. The best CUT-OFF value was 1.850 pg/mL. Conclusion: The measurement of serum SARS-COV-2 N protein has a high diagnostic value for infected patients before the antibody appears and shortens the window period of serological diagnosis. It is recommended that the manufacturer establish two different CUT-OFF values according to the purpose of the application. One CUT-OFF value is used for the diagnosis of clinical SARS-COV-2 infection, and the other is used to screen out as many suspected cases as possible. |
Author | Xu, Yuanhong Li, Tao Wang, Li Wei, Wei Zhang, Shubing Li, Xuemei Wang, Huihui |
AuthorAffiliation | 3 Biohit Healthcare (Hefei) Co., Ltd , Hefei , China 1 Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University , Hefei , China 2 Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Anhui Anti-inflammatory and Immune Medicine Innovation Team, Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China |
AuthorAffiliation_xml | – name: 3 Biohit Healthcare (Hefei) Co., Ltd , Hefei , China – name: 1 Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University , Hefei , China – name: 2 Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-inflammatory and Immune Medicine, Anhui Anti-inflammatory and Immune Medicine Innovation Team, Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China |
Author_xml | – sequence: 1 givenname: Tao surname: Li fullname: Li, Tao – sequence: 2 givenname: Li surname: Wang fullname: Wang, Li – sequence: 3 givenname: Huihui surname: Wang fullname: Wang, Huihui – sequence: 4 givenname: Xuemei surname: Li fullname: Li, Xuemei – sequence: 5 givenname: Shubing surname: Zhang fullname: Zhang, Shubing – sequence: 6 givenname: Yuanhong surname: Xu fullname: Xu, Yuanhong – sequence: 7 givenname: Wei surname: Wei fullname: Wei, Wei |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33014893$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk1v1DAQhi1UREvpnRPKkUsWf8SJwwFptRRYqVBEgKs1cSaLS2Jv7aTS_nuS3RZtkfBlxva8z1ie9zk5cd4hIS8ZXQihyjetsX294JTTBaVZQZ-QM86FTHmp1MlRfkouYryh0yooV6V4Rk6FoCyb0jMyVhjGPqmW36p0df0z5cmX0XToDWyjbZKvwQ9o3dtkmVTooh3snR12CbgmqbZobGvNvL-E0O2S9xY2zsfBmuQzhN8YktaHY_TatWgG690L8rSFLuLFfTwnPz5cfl99Sq-uP65Xy6vUSK6GVHDayBpk3kqUyEqsJTVQG5kDYJurXLJCNgb4FEpaM5MpBSiVKhiHErg4J-sDt_Fwo7fB9hB22oPV-wMfNhrC9N4ONRdQ8lpgWwqeNZzVjWkBKZUZy0ByObHeHVjbse6xMeiGAN0j6OMbZ3_pjb_TRVYqmc-A1_eA4G9HjIPubTTYdeDQj1HzLFO5kCxXU-mr415_mzzMbSrIDwUm-BgDtnqaA8xfO7W2nWZUzx7Re4_o2SN675FJSP8RPrD_K_kDc5i-5g |
CitedBy_id | crossref_primary_10_1002_jev2_12412 crossref_primary_10_1016_j_talanta_2024_126709 crossref_primary_10_1111_crj_13331 crossref_primary_10_7717_peerj_15515 crossref_primary_10_1093_ofid_ofae561 crossref_primary_10_1016_j_isci_2024_110177 crossref_primary_10_1021_acssynbio_0c00566 crossref_primary_10_1109_JSEN_2023_3274110 crossref_primary_10_12688_f1000research_122161_1 crossref_primary_10_1016_j_isci_2024_108976 crossref_primary_10_1016_j_trac_2024_117609 crossref_primary_10_12688_f1000research_122161_2 crossref_primary_10_1016_j_bios_2021_113922 crossref_primary_10_1021_acs_analchem_4c04225 crossref_primary_10_1097_IM9_0000000000000071 crossref_primary_10_3390_chemosensors10070287 crossref_primary_10_1016_j_ijbiomac_2024_129523 crossref_primary_10_1016_j_bios_2021_113160 crossref_primary_10_1017_S1431927621005134 crossref_primary_10_3390_v13061115 crossref_primary_10_1021_acs_analchem_1c04966 crossref_primary_10_3390_v14081653 crossref_primary_10_1016_j_isci_2023_105995 crossref_primary_10_1002_anie_202203662 crossref_primary_10_1021_acssensors_0c02561 crossref_primary_10_1093_ofid_ofad346 crossref_primary_10_1128_spectrum_03410_23 crossref_primary_10_3390_ijms231911589 crossref_primary_10_1038_s41467_021_26652_7 crossref_primary_10_3390_v14061141 crossref_primary_10_1021_acs_analchem_1c04296 crossref_primary_10_1039_D1AN01350E crossref_primary_10_3389_fonc_2022_923467 crossref_primary_10_1021_acsomega_1c04012 crossref_primary_10_3390_bios11090310 crossref_primary_10_1093_clinchem_hvab148 crossref_primary_10_1128_JVI_01396_21 crossref_primary_10_1002_ange_202203662 crossref_primary_10_3390_diagnostics14060642 crossref_primary_10_3390_molecules28052104 crossref_primary_10_1093_ofid_ofac563 crossref_primary_10_1007_s00296_023_05489_x crossref_primary_10_3390_microorganisms9112214 crossref_primary_10_1080_23744235_2024_2382263 crossref_primary_10_52396_JUSTC_2022_0020 crossref_primary_10_1016_j_bios_2021_113029 crossref_primary_10_3389_fimmu_2022_827146 crossref_primary_10_1021_acssensors_2c00317 crossref_primary_10_1016_j_aca_2023_341838 crossref_primary_10_1021_acssensors_3c01093 crossref_primary_10_1016_j_trac_2023_117473 crossref_primary_10_3390_diagnostics13091549 crossref_primary_10_1016_j_snb_2023_133331 crossref_primary_10_2217_fvl_2021_0211 crossref_primary_10_1128_JCM_01001_21 crossref_primary_10_1128_msphere_00067_23 crossref_primary_10_1002_smll_202301162 crossref_primary_10_3390_ijms24087174 crossref_primary_10_1016_j_snb_2021_130739 crossref_primary_10_1021_acscentsci_2c01263 crossref_primary_10_1007_s13404_023_00338_y crossref_primary_10_1186_s12964_024_01665_z crossref_primary_10_1093_infdis_jiac225 crossref_primary_10_3389_fmed_2021_615099 crossref_primary_10_1016_j_cca_2024_119951 crossref_primary_10_1186_s12985_023_01968_6 crossref_primary_10_1002_jmv_27520 crossref_primary_10_1021_acs_analchem_1c04470 crossref_primary_10_1186_s12951_021_01032_x crossref_primary_10_1080_19420862_2021_1905978 crossref_primary_10_3390_vaccines10040516 crossref_primary_10_3389_fonc_2024_1346312 crossref_primary_10_3390_life12050649 crossref_primary_10_1515_rams_2023_0105 crossref_primary_10_3390_diagnostics12102427 crossref_primary_10_1002_14651858_CD013652_pub2 |
Cites_doi | 10.1093/cid/ciaa489 10.1002/eji.202048715 10.1016/j.nmni.2020.100713 10.14293/S2199-1006.1.SOR-.PPA94RC.v1 10.1681/ASN.2020040432 10.1101/2020.05.24.20111849 10.1148/radiol.2020200343 10.2807/1560-7917.ES.2020.25.9.2000173 10.2807/1560-7917.ES.2020.25.3.2000045 10.3760/cma.j.cn112151-20200312-00193 10.1080/22221751.2020.1762515 10.1093/infdis/jiaa243 10.1128/JCM.00310-20 10.1021/acs.analchem.0c01975 10.2807/1560-7917.ES.2020.25.6.2000082 10.1016/S1473-3099(20)30196-1 10.2214/AJR.20.22959 10.1016/S0140-6736(20)30183-5 |
ContentType | Journal Article |
Copyright | Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei. Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei. 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei |
Copyright_xml | – notice: Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei. – notice: Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei. 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.3389/fcimb.2020.00470 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2235-2988 |
ExternalDocumentID | oai_doaj_org_article_23a92b3ef9324d21bdcfae005414a525 PMC7498565 33014893 10_3389_fcimb_2020_00470 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Scientific Research Project of Anhui Medical University for the Prevention and Control of New Coronavirus Pneumonia grantid: YJGG202002 – fundername: Scientific Research Project of Anhui Province for the Prevention and Control of New Coronavirus Pneumonia grantid: 202004a07020015 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN AIAGR ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE INR KQ8 M48 M~E OK1 PGMZT RPM CGR CUY CVF ECM EIF IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c528t-320d5ba56f5e5e19eb50cabc56aaef6865175dca217590b1c488ae588712a9a23 |
IEDL.DBID | M48 |
ISSN | 2235-2988 |
IngestDate | Wed Aug 27 01:27:17 EDT 2025 Thu Aug 21 13:55:35 EDT 2025 Fri Jul 11 02:55:02 EDT 2025 Thu Apr 03 07:02:07 EDT 2025 Thu Apr 24 22:51:56 EDT 2025 Tue Jul 01 04:32:25 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 colloidal gold immunochromatography nucleocapsid protein SARS-CoV-2 diagnostic value |
Language | English |
License | Copyright © 2020 Li, Wang, Wang, Li, Zhang, Xu and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c528t-320d5ba56f5e5e19eb50cabc56aaef6865175dca217590b1c488ae588712a9a23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Clinical Microbiology, a section of the journal Frontiers in Cellular and Infection Microbiology Edited by: Alix Thérèse Coste, Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland Reviewed by: Brian Carey, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), United States; Riti Sharan, Texas Biomedical Research Institute, United States |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fcimb.2020.00470 |
PMID | 33014893 |
PQID | 2448635168 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_23a92b3ef9324d21bdcfae005414a525 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7498565 proquest_miscellaneous_2448635168 pubmed_primary_33014893 crossref_citationtrail_10_3389_fcimb_2020_00470 crossref_primary_10_3389_fcimb_2020_00470 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-09-04 |
PublicationDateYYYYMMDD | 2020-09-04 |
PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-04 day: 04 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in cellular and infection microbiology |
PublicationTitleAlternate | Front Cell Infect Microbiol |
PublicationYear | 2020 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | B10 B13 Qu (B14) 2020 Konrad (B11) 2020; 25 Li (B12) 2020 Tripathi (B19) 2020; 28 Sun (B17) 2020; 9 Zainol Rashid (B22) 2020; 42 Cai (B2) 2020 Xie (B20) 2020; 296 Abduljalil (B1) 2020; 36 Shen (B16) 2020; 12 Reusken (B15) 2020; 25 Chan (B3) 2020; 58 Grant (B7) 2020; 92 To (B18) 2020; 20 Corman (B5) 2020; 25 Farkash (B6) 2020; 31 Haljasmägi (B8) 2020 Huang (B9) 2020; 395 Yao (B21) 2020; 49 Cheng (B4) 2020; 215 |
References_xml | – year: 2020 ident: B14 article-title: Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) publication-title: Clin. Infect. Dis doi: 10.1093/cid/ciaa489 – ident: B13 – ident: B10 – year: 2020 ident: B8 article-title: LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins publication-title: Eur. J. Immunol. doi: 10.1002/eji.202048715 – volume: 36 start-page: 100713 year: 2020 ident: B1 article-title: Laboratory diagnosis of SARS-CoV-2: available approaches and limitations publication-title: N. Microb. N. Infect. doi: 10.1016/j.nmni.2020.100713 – volume: 28 start-page: 18 year: 2020 ident: B19 article-title: COVID 19 diagnostic multiplicity and its role in community surveillance and control publication-title: Infez. Med doi: 10.14293/S2199-1006.1.SOR-.PPA94RC.v1 – volume: 31 start-page: 1683 year: 2020 ident: B6 article-title: Ultrastructural evidence for direct renal infection with SARS-CoV-2 publication-title: J. Am. Soc. Nephrol. doi: 10.1681/ASN.2020040432 – year: 2020 ident: B12 article-title: Serum SARS-COV-2 nucleocapsid protein:a sensitivity and specificity early diagnostic marker for SARS-COV-2 infection publication-title: MedRxiv. doi: 10.1101/2020.05.24.20111849 – volume: 296 start-page: E41 year: 2020 ident: B20 article-title: Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing publication-title: Radiology doi: 10.1148/radiol.2020200343 – volume: 25 start-page: 2000173 year: 2020 ident: B11 article-title: Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2020.25.9.2000173 – volume: 25 start-page: 2000045 year: 2020 ident: B5 article-title: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2020.25.3.2000045 – volume: 49 start-page: 411 year: 2020 ident: B21 article-title: A pathological report of three COVID-19 cases by minimally invasive autopsies publication-title: Zhonghua Bing Li Xue Za Zhi doi: 10.3760/cma.j.cn112151-20200312-00193 – volume: 9 start-page: 940 year: 2020 ident: B17 article-title: Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients publication-title: Emerg. Microbes Infect doi: 10.1080/22221751.2020.1762515 – year: 2020 ident: B2 article-title: A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019 (COVID-19) publication-title: J Infect Dis doi: 10.1093/infdis/jiaa243 – volume: 42 start-page: 13 year: 2020 ident: B22 article-title: Diagnostic performance of COVID-19 serology assays publication-title: Malays. J. Pathol. – volume: 58 start-page: e00310 year: 2020 ident: B3 article-title: Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.00310-20 – volume: 92 start-page: 11305 year: 2020 ident: B7 article-title: A SARS-CoV-2 coronavirus nucleocapsid antigen-detecting half-strip lateral flow assay towards the development of point of care tests using commercially available reagents publication-title: Anal Chem. doi: 10.1021/acs.analchem.0c01975 – volume: 12 start-page: 1348 year: 2020 ident: B16 article-title: Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG publication-title: Am. J. Transl. Res. – volume: 25 start-page: 2000082 year: 2020 ident: B15 article-title: Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2020.25.6.2000082 – volume: 20 start-page: 565 year: 2020 ident: B18 article-title: Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study publication-title: Lancet Infect. Dis doi: 10.1016/S1473-3099(20)30196-1 – volume: 215 start-page: 121 year: 2020 ident: B4 article-title: Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai, China publication-title: Am. J. Roentgenol doi: 10.2214/AJR.20.22959 – volume: 395 start-page: 497 year: 2020 ident: B9 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 |
SSID | ssj0000702893 |
Score | 2.4907858 |
Snippet | To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early stages of... Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early... Objective: To explore the diagnostic value of serum severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein assay in the early... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 470 |
SubjectTerms | Antibodies, Viral - blood Betacoronavirus - isolation & purification Biomarkers - blood Cellular and Infection Microbiology Clinical Laboratory Techniques - methods colloidal gold immunochromatography Coronavirus Infections - blood Coronavirus Infections - diagnosis Coronavirus Nucleocapsid Proteins COVID-19 COVID-19 Testing diagnostic value Enzyme-Linked Immunosorbent Assay - methods Female Humans Male nucleocapsid protein Nucleocapsid Proteins - blood Pandemics Phosphoproteins Pneumonia, Viral - blood Pneumonia, Viral - diagnosis Pregnancy SARS-CoV-2 Sensitivity and Specificity |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELUqJKReUKEfBAoyUi8col07cWL3tkARIJWibqm4WbYzUVcqAcHuof--M3ZYZauqXHpM4tiWZ8bzRh6_YeyDhrEBGVSuITR5iRqMNtc2eYGbZTDBVSLQfefPl9XZdXlxo24Gpb4oJyzRA6eFG8nCGekLaBFolI0UvgmtA0IaonRKRvZS9HmDYCruwTWdoBXpXBKjMDNqw-zWYzwoKZWrpNrEAz8U6fr_hjH_TJUc-J7TV2yjB418kia7yV5At8XWUxnJX6_ZAg1-ccunk6_T_PjL91zyS2IpRi91j7rGr4iKYdZ95BM-pXT1VC-Cu67hsfo8cUjgc6Q65icp9Q4H4nSNBx44otph1-d99lb3hl2ffvp2fJb35RTyoKSe54UcN8o7VbUKFAgDXo2D80FVzkFb6UohlGiCwyBFmbEXAW3bgcJdSEhnnCzesrXuroNtxjHmMVBj6NI2pqy18pUT2KP3GqBWTmRs9LS4NvRc41Ty4qfFmIPEYaM4LInDRnFk7HD5x33i2fhH2yOS17IdMWTHF6g3ttcb-5zeZOzgSdoWLYqOSVwHd4tHi4BHIwwTlc7YuyT95VAFRaCoWBmrV_RiZS6rX7rZj8jaXZdGI3re-R-T32UvaTlirlv5nq3NHxawh-Bo7vejHfwGeI4MtQ priority: 102 providerName: Directory of Open Access Journals |
Title | Serum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33014893 https://www.proquest.com/docview/2448635168 https://pubmed.ncbi.nlm.nih.gov/PMC7498565 https://doaj.org/article/23a92b3ef9324d21bdcfae005414a525 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELbQ0NBeEIwfC4zJSLzwEFY7cWIjTaj7pYG0gShFe7Ns5wKVtnR0rcT-e-6ctKxT4TFN4rS5O9_31efvGHujoWdABpVqCFWaowdjzNVVmuFkGUxwhQi03_n0rDgZ5p_O1fnf7dHdC7xeSe2on9RwcvHu96-bDxjwe8Q4Md_u1mF06ZHqSarSyksk8PcxL5XUz-C0A_txXi5pVS1r1ypX3rjBHmREMbTJltJUVPNfBUHvVlLeSk3Hj9jDDlPyfusEj9k9aDbZettl8uYJm-F8MLvkg_7XQXrw-Xsq-RmJGGMSu0JX5F9IqWHUvOd9PqBq9radBHdNxWNzepKYwOOohMwP28o8fBCnXT4w4Qh6bw_9sSvuap6y4fHRt4OTtOu2kAYl9TTNZK9S3qmiVqBAGPCqF5wPqnAO6kIXCpFGFRxyGGV6XgQMfQcKJykhnXEye8bWmnEDW4wjJTJQIrOpK5OXWvnCCRzRew1QKicStjt_uTZ0UuTUEePCIiUhy9hoGUuWsdEyCXu7uOOqleH4z7X7ZK_FdSSgHT8YT37YLh6tzJyRPoMa8WteSeGrUDsgACtyp6RK2Ou5tS0GHK2iuAbGs2uLeEgjShOFTtjz1vqLR829J2Hlkl8sfZflM83oZxT1LnOjEVy_-OeYL9kG_cZY35Zvs7XpZAavEBBN_U78I2EnevsfdNUImA |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+SARS-COV-2+Nucleocapsid+Protein%3A+A+Sensitivity+and+Specificity+Early+Diagnostic+Marker+for+SARS-COV-2+Infection&rft.jtitle=Frontiers+in+cellular+and+infection+microbiology&rft.au=Li%2C+Tao&rft.au=Wang%2C+Li&rft.au=Wang%2C+Huihui&rft.au=Li%2C+Xuemei&rft.date=2020-09-04&rft.eissn=2235-2988&rft.volume=10&rft.spage=470&rft_id=info:doi/10.3389%2Ffcimb.2020.00470&rft_id=info%3Apmid%2F33014893&rft.externalDocID=33014893 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2235-2988&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2235-2988&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2235-2988&client=summon |